BR0009016A - Composição de apomorfina e sildenafil - Google Patents

Composição de apomorfina e sildenafil

Info

Publication number
BR0009016A
BR0009016A BR0009016-6A BR0009016A BR0009016A BR 0009016 A BR0009016 A BR 0009016A BR 0009016 A BR0009016 A BR 0009016A BR 0009016 A BR0009016 A BR 0009016A
Authority
BR
Brazil
Prior art keywords
sildenafil
apomorphine
administered
composition
treatment
Prior art date
Application number
BR0009016-6A
Other languages
English (en)
Inventor
Ragab El-Rashidy
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Publication of BR0009016A publication Critical patent/BR0009016A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSIçãO DE APOMORFINA E SILDENAFIL". Tratamento de disfunção sexual em pacientes humanos através de um regime de terapia oral de administração de apomorfina e sildenafil é disposto. Esse tratamento otimiza a eficácia de cada droga e substancialmente minimiza os efeitos colaterais indesejáveis associados a eles individualmente. A apomorfina e o sildenafil podem ser co-administrados com uma unidade de dosagem de combinação ou administrada seq³encialmente em unidades de dosagem separadas, substancialmente antes da atividade sexual. Outro agente eretogênico pode ser administrado com apomorfina e sildenafil.
BR0009016-6A 1999-03-16 2000-03-14 Composição de apomorfina e sildenafil BR0009016A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/270,035 US6087362A (en) 1999-03-16 1999-03-16 Apomorphine and sildenafil composition
PCT/US2000/006654 WO2000054774A1 (en) 1999-03-16 2000-03-14 Apomorphine and sildenafil composition

Publications (1)

Publication Number Publication Date
BR0009016A true BR0009016A (pt) 2002-04-16

Family

ID=23029614

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009016-6A BR0009016A (pt) 1999-03-16 2000-03-14 Composição de apomorfina e sildenafil

Country Status (21)

Country Link
US (1) US6087362A (pt)
EP (1) EP1173178B1 (pt)
JP (1) JP2002539163A (pt)
CN (1) CN1350454A (pt)
AT (1) ATE302003T1 (pt)
AU (1) AU3744500A (pt)
BR (1) BR0009016A (pt)
CA (1) CA2367605A1 (pt)
CZ (1) CZ20013344A3 (pt)
DE (1) DE60022021T2 (pt)
DK (1) DK1173178T3 (pt)
ES (1) ES2244418T3 (pt)
HU (1) HUP0200549A3 (pt)
IL (1) IL145487A0 (pt)
MX (1) MXPA01009332A (pt)
NO (1) NO324511B1 (pt)
NZ (1) NZ514464A (pt)
PL (1) PL350313A1 (pt)
PT (1) PT1173178E (pt)
WO (1) WO2000054774A1 (pt)
ZA (1) ZA200107920B (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US6428769B1 (en) * 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
MXPA03001858A (es) * 2000-08-30 2004-05-21 Unimed Pharmaceuticals Inc Metodo para el tratamiento de la disfuncion erectil e incremento en el libido del hombre.
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
JP2004520389A (ja) * 2001-02-08 2004-07-08 ファルマシア・コーポレーション 性的不全の治療のための早期効果発現薬剤
ES2180446B1 (es) * 2001-07-02 2004-01-16 Esteve Labor Dr Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil.
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
ES2302835T3 (es) * 2001-08-28 2008-08-01 Schering Corporation Inhibidores de fosfodiesterasa v policiclicos de guanina.
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
US20030216407A1 (en) * 2002-01-31 2003-11-20 Pfizer Inc. Use of PDE5 inhibitors in the treatment of scarring
EP1496915A1 (en) * 2002-03-19 2005-01-19 Brain 'N' Beyond Biotech Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US7037257B1 (en) * 2002-08-22 2006-05-02 Koenig J Frank Erectile dysfuction treatments comprising momentary vacuum therapy alone or with medications
TWI330529B (en) * 2003-01-13 2010-09-21 Horphag Res Luxembourg Holding Sa A preparation for improving sperm quality or fertility,a kit comprising the same and uses thereof
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
US7306812B2 (en) * 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
DE10325813B4 (de) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
SI1750766T1 (sl) * 2004-05-11 2013-11-29 Emotional Brain B.V. Farmacevtske formulacije in njihove uporabe pri zdravljenju spolne disfunkcije pri Ĺľenskah
CA2749235C (en) * 2004-10-20 2014-08-12 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
BRPI0617294B8 (pt) 2005-10-12 2021-05-25 Besins Healthcare Lu Sarl composição farmacêutica em gel hidroalcóolico e uso de testosterona
BRPI0807282A2 (pt) * 2007-02-12 2014-04-29 Dmi Biosciences Inc Tratamento de ejaculação precoce e disfunção erétil co-mórbidas
EP2486921A1 (en) * 2007-02-12 2012-08-15 DMI Biosciences, Inc. Reducing Side Effects of Tramadol
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
GB0715285D0 (en) * 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
PT2238168E (pt) * 2007-12-26 2014-07-18 Biotest Ag Agentes visando cd138 e suas utilizações
PL2242772T3 (pl) * 2007-12-26 2015-05-29 Biotest Ag Immunokonjugaty nakierowane na CD138 i ich zastosowanie
ES2543201T3 (es) * 2007-12-26 2015-08-17 Biotest Ag Métodos y agentes que mejoran la dirección a las células tumorales que expresan CD138
AR069979A1 (es) * 2007-12-26 2010-03-03 Biotest Ag Metodo para disminuir los efectos secundarios citotoxicos y mejorar la eficacia de los inmunoconjugados
US20090246298A1 (en) * 2008-03-31 2009-10-01 Ceola P. Steele Viagra
US20100184722A1 (en) * 2008-12-19 2010-07-22 Shimoda Biotech (Pty) Ltd Inclusion complexes of alpha-cyclodextrin and sildenafil salt
MX345953B (es) * 2009-05-06 2017-01-27 Biotest Ag Usos de inmunoconjugados dirigidos a cd138.
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
EP2952191B1 (en) * 2009-06-12 2018-08-22 Sunovion Pharmaceuticals Inc. Sublingual apomorphine
WO2012000634A1 (de) 2010-06-29 2012-01-05 Georg Bambach Pharmazeutische zusammensetzung zur behandlung von erektiler dysfunktion
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
CA3115378A1 (en) 2010-12-16 2012-06-21 Sunovion Pharmaceuticals Inc. Sublingual films comprising apomorphine and an organic base
CN104302324A (zh) 2011-12-08 2015-01-21 生物测试股份公司 靶向cd138的免疫偶联物的用途
WO2016172095A1 (en) 2015-04-21 2016-10-27 Cynapsus Therapeutics, Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
ATE312609T1 (de) * 1994-04-22 2005-12-15 Pentech Pharmaceuticals Inc Sublinguale zusammensetzung enthaltend apomorphine zur diagnose der funktionellen impotenz
GB9612514D0 (en) * 1996-06-14 1996-08-14 Pfizer Ltd Novel process
ATE333279T1 (de) * 1997-05-19 2006-08-15 Zonagen Inc Kombinationstherapie zur modulation der humanen sexualreaktion
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction

Also Published As

Publication number Publication date
CN1350454A (zh) 2002-05-22
ZA200107920B (en) 2003-03-26
NO20014519D0 (no) 2001-09-17
US6087362A (en) 2000-07-11
EP1173178A1 (en) 2002-01-23
ES2244418T3 (es) 2005-12-16
EP1173178A4 (en) 2002-09-04
PT1173178E (pt) 2005-11-30
EP1173178B1 (en) 2005-08-17
DK1173178T3 (da) 2005-11-07
WO2000054774A1 (en) 2000-09-21
DE60022021T2 (de) 2006-06-08
ATE302003T1 (de) 2005-09-15
MXPA01009332A (es) 2002-06-21
CZ20013344A3 (cs) 2002-08-14
NZ514464A (en) 2004-01-30
HUP0200549A2 (hu) 2002-07-29
AU3744500A (en) 2000-10-04
PL350313A1 (en) 2002-12-02
DE60022021D1 (de) 2005-09-22
NO324511B1 (no) 2007-11-05
NO20014519L (no) 2001-10-25
HUP0200549A3 (en) 2004-07-28
CA2367605A1 (en) 2000-09-21
IL145487A0 (en) 2002-06-30
JP2002539163A (ja) 2002-11-19

Similar Documents

Publication Publication Date Title
BR0009016A (pt) Composição de apomorfina e sildenafil
EA200300046A1 (ru) Быстро увеличивающаяся в объеме композиция для удерживания и контролированного выделения терапевтических агентов в желудке и лекарственные формы, включающие композицию
JP2002522485A5 (pt)
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
BRPI0510862A (pt) medicamento para tratar disfunção sexual em um paciente, medicamento para tratar disfunção erétil em um paciente, medicamento para diminuir os efeitos colaterais associados com os agentes terapêuticos para tratar a disfunção sexual em um paciente, método para fabricação de um medicamento para tratamento da disfunção sexual de um paciente responsivo marginalmente ao inibidor de pde5, e uso do peptìdeo ac-nle-ciclo (-asp-his-d-phe-arg-trp-lys) -0h na perparação de um medicamento
RU2006139819A (ru) Применение симетикона для предрасположенных к запорам пациентов
HK1077215A1 (en) A pharmaceutical composition for treatment of acute myocardial infarction
AR012731A1 (es) Uso de un derivado de taxano para la preparacion de una composicion farmaceutica , uso de un agente mejorador de la biodicponibilidad de dicho derivado forma de dosificacion oral y conjunto afrmaceutico que lo comprende y metodo para formar a un agente activo biodisponible.
CO5251425A1 (es) Metodo y composiciones para administrar taxanos oralmente a pacientes humanos
NO20001828L (no) Metode for Õ forhindre nefrotoksisitet forÕrsaket av cyklosporiner og tacrolimus
AR023185A1 (es) Tratamiento de cancer mejorado con temozolomida
YU61598A (sh) Tretmani bolesti uz korišćenje citokina
FI20011464A0 (fi) Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
Miller et al. Successful treatment of actinomycosis with stilbamidine
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
AR029160A1 (es) El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
BE1002256A3 (fr) Medicaments.
JP2001316293A5 (pt)
HUP9901935A2 (hu) Gyógyszerek és terápiás szerek és más glikozaminoglikánok (GAG) dózisainak célbajuttatására alkalmas dóziskészlet
MX2023008155A (es) Regimenes de tratamiento con dosis fijas de tamibaroteno.
James AZT twice-daily tablets approved: dosing concerns
BRPI0503488A (pt) agente de tratamento para sìndrome de intestino irritável com diarréia predominante
RU2002129097A (ru) Комбинированные терапии с использованием активности, повреждающей сосуды
CO5170404A1 (es) Terapia para melanomas
CS264081B1 (cs) Analgetický přípravek a anxiolytikem

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 10(VIII), 11, 13, 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.